1st Jul 2022 13:40
ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Negotiates a supplemental terms agreement with Shanghai Fosun Pharmaceutical Group Co Ltd. Company says the agreement has the potential to generate revenue of up to GBP6 million.
The agreement relates to ReNeuron's stroke disability programme. ReNeuron expects to receive around GBP1 million over the next 24 months for the supply of CTX cell bank vials and services, with a further GBP5 million receivable over the medium to long term for continued provision of these vials.
Current stock price: 27.90 pence, up 0.5% in London on Friday
12-month change: down 74%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
RENE.L